Massive data hack on 60 clinics hidden from patients The Australian

Latigo Bio’s IPO Lands $346M for Pipeline of Non-Opioid Pain Drugs
Latigo Biotherapeutics will apply the IPO proceeds toward a pipeline that includes a next-generation non-opioid pain drug ready for pivotal testing. BlossomHill Therapeutics also debuted


